AIBNi014-A

Flagged for further review

hONS-derived A-T iPSC, A-T HL iPSC, ONS-derived A-T iPSC

Details

Tissue & Disease as reported

Biopsy Location
Ontology ID: fma59684
Label: Mucosa of nose
Definition:
Tissue for derived iPSC
Disease as reported (External Source)
ataxia telangiectasia

Genetic Information

Genotype Locus
ATM
Polymorphism
Homozygous: NM_000051.3:c.1236-3dupT; Heterozygous: NM_000051.3:c.6404_6405insTT(p.Arg2136fs)

Line Custodianship

Cell Line Maintainer

Ernst Wolvetang

Affiliated Institutions
  • Australian Institute for Bioengineering and Nanotechnology, Brisbane, Australia
View all cell lines from this group

Cell Line Producer

Australian Institute for Bioengineering and Nanotechnology

Affiliated Institutions
  • Australian Institute for Bioengineering and Nanotechnology, Brisbane, Australia

Derivation Details

Induced Pluripotent Cell Derivation Details

Source Cell Type: EFO:0005705
Label: olfactory neurosphere cell line
Definition: Nasal biopsies were collected from volunteer donors as an outpatient procedure as described (Feron et al., 1998). This was done by a registered otolaryngologist via an endoscopic procedure to ensure biopsy samples were taken from the superior, posterior region of the nasal septum close to the cribriform plate. Pieces of olfactory mucosa were obtained which contain stem cells in the olfactory epithelium. The stem cell population derived from human olfactory mucosa has been described as ecto-mesenchymal (Delorme et al., 2010) because it has characteristics of both neural and mesenchymal stem cells, suggesting a neural crest origin.

Source Cell Origin: UBERON:0005386
Label: olfactory segment of nasal mucosa
Definition: That portion of the nasal mucosa containing the sensory endings for olfaction; the organ of smell[MESH].

Derivation Year: 2018

Reprogramming Method

Vector Type:

Vector: Other

Kit: [kit] ReproRNA-OKSGM

Detected: Unknown

Ethics

Ethics Number: HREC/09/QRCH/103

Institution Human Research Ethics Council: Queensland Children's Health Services Human Ethics Committee

Approval Date: To be verified

Modifications

No genomic modifications available for this line.

Quality Assurance

Genomic Characterisation

Passage Number: 5

Karyotype: 46,XX

Karyotype Method: G-banding

Summary: Karyotyping occurred from passage 5 at a resolution of 500bphs.

STR analysis Results:

Performed but not available.

Microbiology and Virology Screening

Disease Result
Mycoplasma Negative

Characterisation of Undifferentiated Cells

Marker Method
NANOG Immunostaining
POU5F1 (OCT-4) Immunostaining
SOX2 Immunostaining
TRA-1-60 Immunostaining
TRA-1-81 Immunostaining

Scorecard Results

Undifferentiated Cells

No available data for this cell line.

Pluripotency

No available data for this cell line.

Pluripotency Characterisation

Endoderm

In vitro directed differentiation

Assessed by: RT-PCR

Markers: CXCR4;FOXA2;SOX17

Mesoderm

In vitro directed differentiation

Assessed by: RT-PCR

Markers: CD34;HAND1;KDR;PDGFRA

Ectoderm

In vitro directed differentiation

Assessed by: RT-PCR

Markers: NR2F2;OTX2;PAX6;VIM

Growth Characteristics

Culture Medium and Growth Conditions

CO2 concentration: 5%

O2 concentration: Unavailable

Medium Items:

  • Base Medium: mTeSR Plus - STEMCELL Technologies
  • Base Coat: Matrigel (hESC Qualified) - Corning

Passage Method: Enzyme-free cell dissociation

External References